TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics is well positioned for upside because BRIUMVI already has FDA approval in relapsing forms of multiple sclerosis and, by May 2026, ENABLE had enrolled >1,000 patients across >100 US sites, supporting a growing real-world evidence base. The Phase 4 data show durable improvements in treatment satisfaction through Week 48 and 99.4% relapse-free status among switchers, with an ARR of 0.011, which strengthens the drug’s payer and infusion-center value proposition. Management also has additional optionality from a small Phase 2 schizophrenia study in 60 patients, while U.S. market share rose to 8% in 1Q26 from 7%, underscoring momentum.

TG Therapeutics is facing a fragile valuation framework because even the bullish DCF relies on aggressive assumptions, including a 12% discount rate, a -25% terminal growth rate, and full or near-full probability of success for Briumvi IV and Briumvi SC. The outlook is weakened by meaningful execution risk: management is not assigning value to other pipeline assets or indications, while safety, efficacy, statistical significance, regulatory, and intellectual property setbacks could materially impair results. Despite commercial-stage status and FDA approval for BRIUMVI in RMS, the dependence on a narrow product base and increasing competition in multiple sclerosis leaves the thesis highly vulnerable.